NCT04119453终止2 期
A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin
Elevar Therapeutics14 个研究点 分布在 2 个国家目标入组 80 人开始时间: 2020年1月22日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 80
- 试验地点
- 14
- 主要终点
- Objective Response Rate (ORR): Percentage of Participants who Achieve Confirmed Complete Response (CR) or Partial Response (PR)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of rivoceranib in adult participants with recurrent or metastatic ACC. All participants may remain on treatment until occurrence of disease progression, unacceptable toxicity, death, the withdrawal of consent from treatment, lost to follow-up or study termination by the Sponsor. When a participant discontinues rivoceranib for any reason, the participant will enter the 24 month survival follow up period until withdrawal of consent from the study, lost to follow up, end of the study or death, whichever occurs earlier.
The maximum duration of the study is estimated to be 48 months and includes screening, treatment, and follow-up phases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed metastatic/recurrent ACC not amenable to potentially curative surgery or radiotherapy
- •Evidence of disease progression by RECIST v1.1
- •Note: Disease progression is defined as one of the following occurring within the 6 months prior to study entry:
- •At least a 20% increase in radiologically or clinically measurable lesions
- •Appearance of any new lesions
- •Presence of at least one measurable target lesion which is evaluable by RECIST v1.1 criteria
- •Participants are eligible if central nervous system (CNS) metastases have been treated and participants are neurologically returned to baseline or neurologically stable in the opinion of Investigator (except for residual signs or symptoms related to the CNS treatment) for at least 4 weeks prior to first dose of study drug administration. In addition, participants must be either off corticosteroids, or on a stable dose or decreasing dose of <20 milligrams (mg) daily prednisone or prednisone equivalent.
- •Note: Only participants with a known history or indication of CNS disease are required to have CNS imaging prior to study entry
- •Adequate organ and marrow function within 14 days prior to the first dose of rivoceranib administration, defined as:
- •Absolute neutrophil count ≥1500/microliters (μL)
- •Platelet count ≥100,000/μL
- •Serum bilirubin ≤1.5× upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0×ULN (≤5.0×ULN, if with liver metastasis)
- •Estimated Creatinine Clearance >50 milliliters (mL)/minute (min) (Cockcroft-Gault)
- •Partial thromboplastin time (PTT), prothrombin time (PT) and international normalized ratio (INR) ≤1.5×ULN
- •Hemoglobin ≥9.0 grams (g)/deciliter (dL)
- •Urinary protein <2+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates proteinuria ≥2+, a 24-hour urine or urine protein/creatinine ratio must be collected and must demonstrate <2 g of protein in 24 hours.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •The ability to understand and the willingness to sign a written informed consent
- •Female participants who are of non-reproductive potential (that is, post-menopausal by history - no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Female participants of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose of rivoceranib.
- •Male and female participants of reproductive potential who agree to use both a highly effective method of birth control (for example, implants, injectables, combined oral contraceptives, some intrauterine devices, complete abstinence, or sterilized partner) and a barrier method (for example condoms, cervical ring, sponge, etc.) during the period of therapy and for 30 days after the final dose of rivoceranib. Female participants should also refrain from breastfeeding and egg donation and males should refrain from sperm donation throughout this period
- •QTc interval <480 milliseconds (ms) (Common Terminology Criteria for Adverse Events [CTCAE] Grade 1) using Fredericia's QT correction formula
排除标准
- •Previous treatment with rivoceranib
- •Known hypersensitivity to rivoceranib or components of the formulation
- •Packed red blood cell transfusion or erythropoietin therapy within 14 days prior to the first dose of rivoceranib administration
- •History of another malignancy within 3 years prior to enrollment. A participant with the following malignancies is eligible for this study if, surgically and medically treated and in the opinion of the investigator, they do not pose a significant risk to life expectancy or not likely to recur within 3 years:
- •Carcinoma of the skin without melanomatous features
- •Curatively treated cervical carcinoma in situ
- •Bladder tumors considered superficial such as noninvasive (T1a) and carcinoma in situ (Tis)
- •Thyroid papillary cancer with prior treatment
- •Prostate cancer which has been surgically or medically treated
- •Prior chemotherapy, radiation therapy or major surgery within 4 weeks prior to rivoceranib administration or presence of any nonhealing wound (procedures such as catheter placement are not considered to be major surgery). Prior immunotherapy within 12 weeks prior to first dose of study drug. Palliative radiotherapy to non-target lesions within 2 weeks prior to rivoceranib administration or biopsy any time prior to rivoceranib administration is permitted.
- •Prior tyrosine kinase inhibitor therapy targeting vascular endothelial growth factor receptors (VEGFR), within 5 half-lives prior to rivoceranib administration
- •Participants who have not recovered to ≤Grade 1 from prior tyrosine kinase inhibitor-related adverse events
- •History of uncontrolled hypertension based on Investigator's clinical judgement (consistent blood pressure readings ≥140/90 millimeters of mercury [mmHg] and/or change in antihypertensive medication within 7 days prior to rivoceranib administration)
- •History of severe adverse events including uncontrolled hypertension or other common anti-angiogenesis class drug effects (for example, ramucirumab) that may indicate a higher risk to the safety of the participant if provided further anti-angiogenesis treatment, in the investigator's opinion.
- •History of vascular disease including arterial or venous embolic events (pulmonary embolism), other than hypertension, within the last 3 months prior to treatment with rivoceranib (for example, hypertensive crisis, hypertensive encephalopathy, stroke or transient ischemic attack [TIA], or significant peripheral vascular diseases) that, in the investigator's opinion, may pose a risk to the participant on vascular endothelial growth factor (VEGF) inhibitor therapy.
- •History of bleeding diathesis or clinically significant bleeding within 14 days prior to treatment with rivoceranib
- •History of clinically significant thrombosis within 3 months prior to treatment with rivoceranib that, in the investigator's opinion, may place the participant at risk of side effects from anti-angiogenesis products
- •Therapy with systemic anticoagulant or antithrombotic agents within 7 days prior to treatment with rivoceranib that in the investigator's opinion could interfere with clotting. The maximum allowable daily dose of aspirin is 325 mg.
- •Gastrointestinal malabsorption, or any other condition that in the opinion of the investigator might affect the absorption of rivoceranib
- •History of clinically significant glomerulonephritis, biopsy-proven tubulointerstitial nephritis, crystal nephropathy, or other renal insufficiencies
- •An uncontrolled intercurrent illness including, but not limited to any of the following:
- •Ongoing or active infection (including minor localized infections) requiring oral or intravenous treatment
- •Symptomatic class 3 or 4 congestive heart failure, defined as a clinical syndrome resulting from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood
- •Unstable angina pectoris
- •Cardiac arrhythmia
- •Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the participant's safety or study endpoints
- •A female participant who is pregnant or breast-feeding
- •Psychiatric illness/social situations that would limit compliance with study requirements
- •History of drug or alcohol abuse within the past 5 years
- •Known seropositive requiring anti-viral therapy for human immunodeficiency virus (HIV) infection
- •Known seropositive requiring antiviral therapy for hepatitis B virus (HBV) infection OR evidence of active hepatitis B infection by detectable viral load if the antibody tests are positive NOTE: A positive hepatitis B core antibody (HBcAb) participant with an undetectable surface antigen and negative hepatitis B deoxyribonucleic acid (DNA) test (for example, polymerase chain reaction [PCR] test) can be enrolled.
- •Known seropositive requiring antiviral therapy for hepatitis C virus (HCV) infection OR participants with positive hepatitis C virus antibody NOTE: A positive Anti-HCV participant with an undetectable/negative hepatitis C ribonucleic acid (RNA) test can be enrolled.
- •Participation in another clinical study with any investigational medication or product administered within ≤28 days prior to first dose of rivoceranib
- •Participants unable or unwilling to discontinue excluded medications for at least 5 half-lives prior to first dose of study drug
研究组 & 干预措施
Rivoceranib
Experimental
Participants will receive an oral dose of rivoceranib once per day during 28-day cycles.
干预措施: Rivoceranib (Drug)
结局指标
主要结局
Objective Response Rate (ORR): Percentage of Participants who Achieve Confirmed Complete Response (CR) or Partial Response (PR)
时间窗: Up to 48 months
ORR per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Independent Central Review.
Objective Response Rate (ORR): Percentage of Participants Who Achieved Confirmed Complete Response (CR) or Partial Response (PR) Per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator/Institutional Assessment
时间窗: Up to 41 months
Complete Response - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm) (the sum may not be "0" if there are target nodes). Partial Response - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
ORR: Percentage of Participants Who Achieve Confirmed CR or PR Per RECIST 1.1 by Independent Central Review
时间窗: Up to 41 months
CR - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (the sum may not be "0" if there are target nodes). PR - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
次要结局
- Overall Survival (OS) at 1 Year and 2 Years(Years 1 and 2)
- Duration of Response (DoR)(Up to 48 months)
- Progression free survival (PFS) at 6 Months, 12 Months, and 2 Years(Months 6 and 12, and Year 2)
- Time to progression (TTP)(Up to 48 months)
- Number of Participants With Adverse Events (AEs)(Up to 48 months)
- Overall Survival (OS) Rate(Months 12 and 24)
- Progression Free Survival (PFS) Rate at 6 Months, 12 Months, and 2 Years by Investigator or Institutional Assessment(Months 6, 12, and 24)
- Progression Free Survival (PFS) at 6 Months, 12 Months, and 2 Years Evaluated by Independent Central Review(Months 6 and 12, and Year 2)
- Duration of Response (DoR) Per RECIST Version 1.1 by Investigator or Institutional Assessment(Up to 41 months)
- Duration of Response (DoR) Per RECIST Version 1.1 Evaluated by Independent Central Review(Up to 41 months)
- Time to Progression (TTP) Per RECIST Version 1.1 by Investigator or Institutional Assessment(Up to 41 months)
- TTP Per RECIST Version 1.1 Evaluated by Independent Central Review(Up to 41 months)
- Number of Participants With Treatment-Emergent Adverse Events (AEs)(From first dose of rivoceranib until 30 days after the last dose date of rivoceranib or initiation of other anticancer therapy, whichever is earlier (up to 41 months))
研究者
研究点 (14)
Loading locations...
相似试验
终止
1 期
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)Metastatic Colorectal CancerNCT04073615Elevar Therapeutics29
已完成
2 期
A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 MutationNeoplasmsNCT01286753Hoffmann-La Roche51
终止
1 期
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer PatientsNCT01309490Jewish General Hospital5
已完成
2 期
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive CancersMultiple Myeloma, NeoplasmsNCT01524978Hoffmann-La Roche208
已完成
2 期
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerNon-small Cell Lung CancerNCT03915951Pfizer98